60
Participants
Start Date
August 15, 2024
Primary Completion Date
February 28, 2025
Study Completion Date
April 30, 2025
Natrunix
Natrunix is a monoclonal antibody preparation. Natrunix antibody is indistinguishable from a natural antibody isolated from a healthy human. Natrunix is expected to be the safest, most effective therapy for alleviating inflammatory pain and mitigating damage, mainly in the spine and sacroiliac joints, in AxSpA patients.
Placebo
Placebo
XBiotech, Inc.
INDUSTRY